Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hypertriglyceridemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    60 result(s) found for: Hypertriglyceridemia. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2005-005698-31 Sponsor Protocol Number: 4/2005 Start Date*: 2006-09-12
    Sponsor Name:National Medical Center (Országos Gyógyintézeti Központ)
    Full Title: Efficacy of fenofibrate treatment on the insulin sensitivity and pancreas ß-cell function in obese patients with hypertriglyceridemia.
    Medical condition: Patients non-diabetic, obese with hypertriglyceridemia (previously untreated with fibrate).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003434-93 Sponsor Protocol Number: ISIS-304801-CS16 Start Date*: 2015-01-07
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Hypertriglyceridemia
    Medical condition: Hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Ongoing) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024064-18 Sponsor Protocol Number: OM-EPA-003 Start Date*: 2011-03-22
    Sponsor Name:Omthera Pharmaceutical Inc.
    Full Title: Efficacy and Safety of Epanova® in Severe Hypertriglyceridemia
    Medical condition: Severe hypertriglyceridemia defined as serum triglyceride (TG) values ≥500 and <2000 mg/dL (≥5.65 mmol/L and <22.60 mmol/L).
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-002536-67 Sponsor Protocol Number: ISIS678354-CS3 Start Date*: 2021-04-15
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA‑APOCIII‑LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
    Medical condition: Familial Chylomicronemia Syndrome (FCS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10059183 Familial hypertriglyceridaemia PT
    20.1 100000004861 10020607 Hyperchylomicronemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) NO (Completed) FR (Completed) PT (Completed) SK (Completed) HU (Completed) NL (Ongoing) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003280-95 Sponsor Protocol Number: ISIS678354-CS13 Start Date*: 2022-06-16
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
    Medical condition: Familial Chylomicronemia Syndrome (FCS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10059183 Familial hypertriglyceridaemia PT
    20.1 100000004861 10020607 Hyperchylomicronemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Trial now transitioned) NO (Completed) PT (Trial now transitioned) FR (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003307-62 Sponsor Protocol Number: R1500-HTG-1522 Start Date*: 2018-07-20
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Placebo-Controlled Study of Safety and Efficacy, Following Repeat-Dose Administration of Evinacumab (anti-ANGPTL3) in Patients with Severe Hypertriglyceridemia (sHTG) at Risk...
    Medical condition: Severe Hypertriglyceridemia (sHTG)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000872-40 Sponsor Protocol Number: CLCQ908C2201 Start Date*: 2012-11-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A pilot study to assess the efficacy and safety of LCQ908 alone and in combination with fenofibrate or Lovaza® in patients with severe hypertriglyceridemia
    Medical condition: Non Familial Chylomicronemia Syndrome (Non-FCS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003353-24 Sponsor Protocol Number: Hx-CD4-110 Start Date*: 2007-04-25
    Sponsor Name:TenX Biopharma, Inc.,
    Full Title: Open-label, Dose escalation, followed by Open-label, Single Arm, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Mycosis Fungoides (stage IB-I...
    Medical condition: Refractory Mycosis Fungoides (stage IB-IVB) and Sézary Syndrome. The study population will be patients who are refractory to or intolerant to at least two prior therapies, one being Targretin, the...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028502 Mycosis fungoides refractory LLT
    9.1 10028508 Mycosis fungoides/Sezary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004682-14 Sponsor Protocol Number: OM-EPA-011 Start Date*: 2014-04-15
    Sponsor Name:Omthera Pharmaceuticals, Inc.
    Full Title: A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
    Medical condition: Severe hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-001921-86 Sponsor Protocol Number: S185.4.001 Start Date*: 2007-07-19
    Sponsor Name:Solvay Pharmaceuticals GmbH
    Full Title: A double-blind, placebo-controlled, parallel-group, multi-center study to investigate the effect of Omacor (n-3 PUFA) on lipid parameters in HIV infected patients treated with HAART
    Medical condition: HAART-induced hypertriglyeridemia in HIV infected subjects
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020869 Hypertriglyceridaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-010520-25 Sponsor Protocol Number: AMR-01-01-0016 Start Date*: 2009-12-08
    Sponsor Name:Amarin Pharma Inc.
    Full Title: A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension to Evaluate the Efficacy and Safety of AMR101 in Patients With Fasting Triglycer...
    Medical condition: Hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014486 Elevated triglycerides HLT
    9.1 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) DK (Prematurely Ended) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000641-13 Sponsor Protocol Number: BIO89-100-221 Start Date*: 2020-09-30
    Sponsor Name:89bio, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects with Severe Hypertriglyceridemia
    Medical condition: Severe Hypertriglyceridemia (SHTG)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003029-11 Sponsor Protocol Number: 2012-489 Start Date*: 2012-09-10
    Sponsor Name:Steen Stender
    Full Title: Ethyl ester Versus Triglyceride formulations of long chained omega-3 fatty acids in moderate hypertriglyceridemia - a randomized placebo-controlled clinical trial (EVT)
    Medical condition: Hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    15.0 10027433 - Metabolism and nutrition disorders 10071235 Combined hyperlipidemia LLT
    15.0 10010331 - Congenital, familial and genetic disorders 10060754 Type IV hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000437-13 Sponsor Protocol Number: R1500-HTG-20118 Start Date*: 2022-01-07
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Evinacumab in Patients with Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
    Medical condition: Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10020869 Hypertriglyceridaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001069-28 Sponsor Protocol Number: D5881C00004 Start Date*: 2015-02-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)
    Medical condition: Severe persistent Hypertriglyceridemia in High Cardiovascular Risk Patients
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) EE (Completed) LT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000687-30 Sponsor Protocol Number: AROAPOC3-2001 Start Date*: 2021-10-04
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Severe Hypertriglyceridemia
    Medical condition: Severe Hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-024182-44 Sponsor Protocol Number: NL3372110110 Start Date*: 2011-01-12
    Sponsor Name:
    Full Title: Pilot study: Leucocyte actIvation and endothelial function after oral fat loading combined with VITamin D
    Medical condition: Endothelial function Leukocyte activation Triglyceride metabolism Skin autofluorescence
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003601 Atherosclerosis LLT
    12.1 10020870 Hypertriglyceridemia LLT
    12.1 10050713 Vitamin D LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002192-19 Sponsor Protocol Number: ISIS678354-CS5 Start Date*: 2022-07-22
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia
    Medical condition: Severe hypertryglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10059183 Familial hypertriglyceridaemia PT
    20.1 100000004861 10020607 Hyperchylomicronemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) BG (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002715-10 Sponsor Protocol Number: FAR-NP-2018-01 Start Date*: 2019-02-08
    Sponsor Name:Elisabet Leiva Badosa. Phamacy Department. Hospital Universitari de Bellvitge
    Full Title: RANDOMIZED, DOUBLE-BLIND, PILOT CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF FISH OIL-BASED INTRAVENOUS LIPID EMULSIONS IN HOSPITALIZED ADULT PATIENTS TREATED WITH TOTAL PARENTERAL NUTRITIO...
    Medical condition: Hypertriglyceridemia is a frequent metabolic complication associated with the administration of lipidic emulsion in total parenteral nutrition.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003168-28 Sponsor Protocol Number: 77458 Start Date*: 2022-06-28
    Sponsor Name:Academic Medical Center (AMC), department of Internal Medicine
    Full Title: Impact of Triglyceride-Lowering on Inflammatory Activity in Patients with Hypertriglyceridemia
    Medical condition: - Hypertriglyceridemia - Inflammation - Lipoproteins
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 10:53:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA